Business
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcastJaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS Ambassadors - cancer survivors who understand the realities of cancer and are no longer willing to accept debilitating side effects of cancer treatments as an acceptable trade-off for survivalCancer patients with diarrhea are 40% more likely to discontinue their therapy; oral mucositis affects up to 40% of patients undergoing chemotherapy and approximately 90% of those receiving chemoradiation for head and neck cancers, with more than one-third of patients discontinuing cancer treatment because of the condition SAN FRANCISCO, CA / ACCESSWIRE / July 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\") today announced that it will hold an investor webcast on Tuesday, July 23, 2024 at 8:30 AM Eastern to review results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. A press release announcing the results will be issued that morning, prior to the webcast. The webcast will provide updates on Jaguar's advancing cancer supportive care portfolio and include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.Participation Instructions for Investor WebcastWhen: Tuesday, July 23, 2024 at 8:30 AM EasternParticipant Registration & Access Link: Click Here\"Patients are the heart of our mission at Jaguar,\" said Lisa Conte, the company's president and CEO. \"We look forward to receiving and providing the OnTarget results with the anticipation we know all our stakeholders share.\"In addition to the forthcoming OnTarget data, the following advances in Jaguar's cancer supportive care portfolio will be discussed during the webcast on July 23:In April 2024, Jaguar entered into an exclusive 5-year U.S. in-license agreement for the FDA-approved oral mucosit...